Clinical trial
A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of APX001 in the Treatment of Patients With Invasive Mold Infections Caused by Aspergillus Species or Rare Molds
NCT04240886 is registered in ClinicalTrials.gov with Basilea Pharmaceutica as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of APX001 in the Treatment of Patients With Invasive Mold Infections Caused by Aspergillus Species or Rare Molds
- Lead sponsor
- Basilea Pharmaceutica
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- January 4, 2020
- Completion date
- May 9, 2022
- Enrollment
- 21 (actual)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.